Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Buys Biotech Antibody Technology From U.S. Firm

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo bought compound-combining technology from Seattle Genetics, a U.S. start-up biotech, for $4 million plus future payments if Daiichi brings drugs to market. Eventually, the Japanese drug maker plans to handle the biotech process on its own, but in the interim is to send antibodies and compounds to Seattle to have them combined and returned to Japan for research and development. Daiichi is interested in cancer-fighting compounds to combine with antibody drugs to make treatments more effective. (Click here for more - a subscripiton may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069058

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel